Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

• Main Authors: Norito Katoh (Author), Masanori Ikeda (Author), Yukihiro Ohya (Author), Hiroyuki Murota (Author), Xiaofei Hu (Author), John Liu (Author), Hayato Niiyama (Author), Takuya Sasaki (Author), Eliza M. Raymundo (Author), Hidehisa Saeki (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD. Methods Rising Up was a phase 3, rand...